PMID- 34714524
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211125
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 12
DP  - 2021 Dec
TI  - Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus 
      Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic 
      Therapy.
PG  - 3231-3241
LID - 10.1007/s13300-021-01156-1 [doi]
AB  - INTRODUCTION: The fixed-ratio combinations (FRCs) of glucagon-like peptide 1 
      receptor agonists (GLP-1 RAs) and basal insulin, insulin glargine 100 U/mL plus 
      lixisenatide (iGlarLixi), and insulin degludec plus liraglutide (iDegLira), have 
      demonstrated safety and efficacy in patients with type 2 diabetes mellitus (T2DM) 
      inadequately controlled on GLP-1 RAs. However, a comparative cost-effectiveness 
      analysis between these FRCs from a UK Health Service perspective has not been 
      conducted. METHODS: The IQVIA Core Diabetes Model was used to estimate lifetime 
      costs and outcomes in patients with T2DM receiving iGlarLixi (based on the 
      LixiLan-G trial) versus iDegLira (based on relative treatment effects from an 
      indirect treatment comparison using data from DUAL III). Utilities, medical 
      costs, and costs of diabetes-related complications were derived from literature. 
      Model outputs included costs and quality-adjusted life years (QALYs). Incremental 
      cost-effectiveness ratios were calculated with a local willingness-to-pay 
      threshold of  pound20,000 per QALY. Extensive scenario, one-way sensitivity, and 
      probabilistic sensitivity analyses were conducted to evaluate the robustness of 
      the model. RESULTS: iGlarLixi was less costly (iGlarLixi,  pound30,011; iDegLira, 
       pound40,742), owing to lower acquisition costs, and similar in terms of QALYs gained 
      (iGlarLixi, 8.437; iDegLira, 8.422). Extensive scenario and sensitivity analyses 
      supported the base case findings. CONCLUSION: In patients with T2DM and 
      inadequate glycemic control despite GLP-1 RAs, use of iGlarLixi was associated 
      with substantial cost savings and comparable utility outcomes. iGlarLixi can be 
      considered as cost-effective versus iDegLira from the UK Health Service 
      perspective.
CI  - (c) 2021. The Author(s).
FAU - McCrimmon, Rory J
AU  - McCrimmon RJ
AD  - School of Medicine, University of Dundee, Dundee, UK.
FAU - Lamotte, Mark
AU  - Lamotte M
AD  - IQVIA Global HEOR, Zaventem, Belgium.
FAU - Ramos, Mafalda
AU  - Ramos M
AD  - IQVIA Global HEOR, Porto Salvo, Portugal.
FAU - Alsaleh, Abdul Jabbar Omar
AU  - Alsaleh AJO
AD  - Department of Economics, University of Bologna, Bologna, Italy.
FAU - Souhami, Elisabeth
AU  - Souhami E
AD  - Sanofi, Paris, France.
FAU - Lew, Elisheva
AU  - Lew E
AD  - Sanofi, Paris, France. Elisheva.Lew@sanofi.com.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20211029
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8586382
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Cost-utility
OT  - GLP-1 receptor agonist
OT  - Type 2 diabetes mellitus
OT  - United Kingdom
OT  - iGlarLixi
EDAT- 2021/10/30 06:00
MHDA- 2021/10/30 06:01
PMCR- 2021/10/29
CRDT- 2021/10/29 12:30
PHST- 2021/08/04 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2021/10/30 06:01 [medline]
PHST- 2021/10/29 12:30 [entrez]
PHST- 2021/10/29 00:00 [pmc-release]
AID - 10.1007/s13300-021-01156-1 [pii]
AID - 1156 [pii]
AID - 10.1007/s13300-021-01156-1 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Dec;12(12):3231-3241. doi: 10.1007/s13300-021-01156-1. Epub 
      2021 Oct 29.